Schnitzer Steel Industries Inc

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.  The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.  Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.  Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Schnitzer Steel Reports Q3 Loss, Focuses on Strategic Growth

Schnitzer Steel is navigating a challenging market landscape with strategic initiatives aimed at improving margins and capitalizing on favorable demand trends. The company is focused on cost control, productivity improvements, and strategic investments to position itself for recovery and growth in a transitioning industry.

Schnitzer Steel Industries Inc doubles EBITDA in Q4 2024

Schnitzer Steel Industries Inc delivered a robust performance in Q4 2024, driven by increased sales volumes and cost-saving initiatives amidst challenging market conditions.
The company showcased strengths in managing operational efficiency, capitalizing on favorable market trends, and maintaining financial flexibility with manageable debt levels.
While facing challenges such as market headwinds and high capital expenditures, Schnitzer Steel has opportunities to further enhance operational efficiency, capitalize on market trends, and drive revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Radius Recycling, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company was founded by Sam Schnitzer in 1906 and is headquartered in Portland, OR.

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall study population and patients whose tumors harbor an ESR1 mutation U.S. FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of February 17, 2023 FLORENCE, Italy and NEW YORK, Aug. 11, 2022 /PRNewswire/ -- The Menarini Group ("Menarini"), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Dave & Buster's

USA Truck

Evolent Health

GAMCO Investors

Ingles Markets

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Dave & Busters, USA Truck See Activist Investor Action

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Radius Health, Inc. (NasdaqGM: RDUS) to Gurnet Point Capital and Patient Square Capital. Under the terms of the proposed transaction, shareholders of Radius will receive only $10.00 per share in cash plus a CVR (Contingent Value Right) of $1.00 per share for each share of Radius that they own. KSF is seeking t

RADIUS HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Radius Health, Inc. - RDUS

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today released the following statement: “While we b

Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health

Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/.

Radius Health Publishes Investor Presentation Outlining Company's Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the first patient has been randomized in the Phase 2/3 pivotal study, SCOUT-015, to evaluate RAD011, a synthetic cannabidiol oral solution, for the treatment of hyperphagia and related neuro-behavioral symptoms in Prader-Willi Syndrome (PWS), a rare neuro-endocrine orphan disease which effects between approximately 20,000 and 30,000 patients in the US.

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

Los Angeles, California--(Newsfile Corp. - July 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. ("Radius" or "the Company") (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management.If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to participate.We also encourage...

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm

NEW YORK , July 5, 2022 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) stock prior to June 23, 2022 . You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Radius by Gurnet Point Capital ("Gurnet Point") and Patient Square Capital ("Patient Square").

RDUS ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Radius Health, Inc. by Gurnet Point Capital and Patient Square Capital

NEW YORK , June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Radius Health, Inc. ("Radius Health" or the "Company") (NASDAQ: RDUS), in connection with the proposed acquisition of the Company by Gurnet Point Capital and Patient Square Capital via tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $ 10.00 per share plus a Contingent Value Right (CVR) of $1.00 per share payable upon TYMLOS® net sales reaching $300 million during any consecutive 12-month period prior to December 31, 2025.

SHAREHOLDER ALERT: Weiss Law Investigates Radius Health, Inc.

Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.

Radius (RDUS) to Go Private With $890M Deal, Shares Gain

Wilmington, Delaware--(Newsfile Corp. - June 24, 2022) - Rigrodsky Law, P.A. is investigating Radius Health, Inc. ("Radius") (NASDAQ: RDUS) regarding possible breaches of fiduciary duties and other violations of law related to Radius' agreement to be acquired by Gurnet Point Capital and Patient Square Capital. Under the terms of the agreement, Radius' shareholders will receive $10.00 in cash and a Contingent Value Right of $1.00 for each share of Radius common stock they own.To learn...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Radius Health, Inc. Merger

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today issued the following comment in response to t

Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital

Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.

Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

Why Radius Health Climbed Today

MILWAUKEE , June 23, 2022 /PRNewswire/ -- Ademi LLP is investigating Radius (NASDAQ: RDUS) for possible breaches of fiduciary duty and other violations of law in its transaction with Gurnet Point and Patient Square.  Click here to learn how to join the action: https://www.ademilaw.com/case/radius-health-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Radius Health, Inc. has obtained a Fair Price in its transaction with Gurnet Point and Patient Square

Radius Health Inc (NASDAQ: RDUS) will be acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of the CVR (Contingent Value Right).  Gurnet Point and Patient.

Bone Health Focused Radius Health Goes Private In $890M Deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Radius Health, Inc. (NASDAQ: RDUS) to Gurnet Point Capital and Patient Square Capital is fair to Radius Health shareholders. Under the terms of the merger agreement, Gurnet Point and Patient Square will acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a Contingent Value Right of $1.00 per share payable upon TYMLOS® (abaloparatide) net sales reaching $30

RDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to Shareholders

BOSTON and CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has entered into a definitive agreement to be acquired by Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of the CVR (Contingent Value Right). Debt financing for this transaction will be provided by OrbiMed Advisors, LLC.

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and currently only, investigational oral SERD with positive topline results Additional data presented at SABCS (December 2021) and ASCO (June 2022) Plan to file marketing authorization application for elacestrant in the EU in 2H 2022 FLORENCE, Italy and BOSTON , June 22, 2022 /PRNewswire/ -- The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RDUS) (collectively, the "Companies") announced that Menarini, with support from Radius, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer. As part of the submission, the Companies have requested Priority Review with the FDA.

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, announced today that it has issued a detailed prese

Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14.62% of the common stock of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today sent a letter to Radius' Board of Directors (the “Board”). In its letter, Rubric outlines the following value enhancing initiatives to address the Company's underperformance and poor corporate governance: Maximize the value of Tymlos Maximize the value

Rubric Capital Management Sends Letter to Radius Health Board of Directors

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today responded to recent statements made by the Ra

Velan-Repertoire Responds to Misleading Characterizations by the Radius Board

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, announced today that it has filed definitive proxy

Velan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual Meeting

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) FLORENCE, Italy and BOSTON , June 6, 2022 /PRNewswire/ -- The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RDUS) (collectively, the "Companies") today announced the presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting of data from the EMERALD phase 3 clinical trial (NCT03778931).

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

News for Schnitzer Steel Industries Inc Stock (RDUS)